down arrow

Corbus Pharmaceuticals Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US21833P3010
USD
10.69
0.41 (3.99%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.5210.80

52 Week

4.6420.56
Valuation
Technical
Day's Volume

CASH

63.8 k

Shareholding (Jun 2025)

FII

9.74%

Held by 37 FIIs

DII

65.57%

Held by 15 DIIs

Promoter

10.99%

How big is Corbus Pharmaceuticals Holdings, Inc.?

22-Jun-2025

As of Jun 18, Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of 101.32 million, with net sales of 0.00 million and a net profit of -50.29 million over the last four quarters. The company's shareholder's funds are 142.43 million, and total assets amount to 155.88 million.

Market Cap: As of Jun 18, Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of 101.32 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Corbus Pharmaceuticals reported net sales of 0.00 million and a net profit of -50.29 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 142.43 million, while total assets were reported at 155.88 million.

Read More

What does Corbus Pharmaceuticals Holdings, Inc. do?

22-Jun-2025

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for rare inflammatory and fibrotic diseases. It has a market cap of $101.32 million and reported a net profit loss of $17 million as of March 2025.

Overview:<BR>Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for rare, chronic, and serious inflammatory and fibrotic diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 101.32 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.03<BR>Return on Equity: -39.57%<BR>Price to Book: 0.80<BR><BR>Contact Details:<BR>Address: 500 RIVER RIDGE DRIVE, NORWOOD MA : 02062<BR>Tel: ['1 617 9630103', '1 617 4157745']<BR>Website: https://www.corbuspharma.com/

Read More

Who are in the management team of Corbus Pharmaceuticals Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Corbus Pharmaceuticals Holdings, Inc. includes Mr. Alan Holmer (Independent Chairman), Mr. Yuval Cohen (CEO), and several Independent Directors: Mr. Avery Catlin, Ms. Rachelle Jacques, Dr. John Jenkins, and Dr. Peter Salzmann. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Corbus Pharmaceuticals Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Alan Holmer, Independent Chairman of the Board<BR>- Mr. Yuval Cohen, Chief Executive Officer and Director<BR>- Mr. Avery Catlin, Independent Director<BR>- Ms. Rachelle Jacques, Independent Director<BR>- Dr. John Jenkins, Independent Director<BR>- Dr. Peter Salzmann, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Corbus Pharmaceuticals Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of March 8, 2022, Corbus Pharmaceuticals is considered overvalued due to its financial metrics, including a Price to Book Value of 0.89 and an EV to EBITDA of 0.32, while its stock has underperformed significantly with a year-to-date return of -33.14%.

As of 8 March 2022, the valuation grade for Corbus Pharmaceuticals Holdings, Inc. moved from risky to does not qualify, indicating a significant change in its perceived investment quality. The company is currently considered overvalued given its financial metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 0.89, and the EV to EBITDA is at 0.32, suggesting that the market may not be accurately pricing the company's potential.<BR><BR>In comparison to its peers, Corbus Pharmaceuticals shows a stark contrast with ASP Isotopes, Inc. and ARCA biopharma, Inc., which have P/E ratios of -24.0140 and -5.3909, respectively. This places Corbus in a challenging position within its industry, where other companies are also struggling. The company's recent stock performance has been notably poor, with a year-to-date return of -33.14%, significantly underperforming the S&P 500's 2.44% return. Overall, the combination of these factors leads to the conclusion that Corbus Pharmaceuticals is overvalued in the current market environment.

Read More

Is Corbus Pharmaceuticals Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Corbus Pharmaceuticals is in a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but significantly underperformed over the past year.

As of 8 September 2025, the technical trend for Corbus Pharmaceuticals Holdings, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are bullish, while the KST is bullish weekly but bearish monthly. Dow Theory indicates no trend weekly and mildly bullish monthly. OBV is mildly bullish across both weekly and monthly periods.<BR><BR>In terms of multi-period returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 22.32% and 25.62% respectively, but it has significantly underperformed over the longer term, with a 1-year return of -76.44% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the bearish monthly indicators and significant long-term underperformance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 121 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.04

stock-summary
Return on Equity

-52.21%

stock-summary
Price to Book

1.09

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.53%
0%
8.53%
6 Months
28.8%
0%
28.8%
1 Year
-36.18%
0%
-36.18%
2 Years
64.46%
0%
64.46%
3 Years
8054.08%
0%
8054.08%
4 Years
-51.85%
0%
-51.85%
5 Years
703.76%
0%
703.76%

Corbus Pharmaceuticals Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Corbus Pharmaceuticals Holdings, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Corbus Pharmaceuticals Holdings, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are bullish, while the KST is bullish weekly but bearish monthly. Dow Theory indicates no trend weekly and mildly bullish monthly. OBV is mildly bullish across both weekly and monthly periods. In terms of multi-period returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 22.32% and 25.62% respectively, but it has significantly underperformed over the longer term, with a 1-year return of -76.44% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish,...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
7.64%
EBIT to Interest (avg)
-51.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.89
EV to EBIT
0.31
EV to EBITDA
0.32
EV to Capital Employed
4.28
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1364.06%
ROE (Latest)
-39.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 26 Schemes (13.69%)

Foreign Institutions

Held by 37 Foreign Institutions (9.74%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -4.12% vs -78.95% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.10",
          "val2": "-19.70",
          "chgp": "3.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.70",
          "val2": "-17.00",
          "chgp": "-4.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.87% vs -5.44% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.10",
          "val2": "-44.40",
          "chgp": "-8.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "2.90",
          "chgp": "-34.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-40.20",
          "val2": "-44.60",
          "chgp": "9.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.10
-19.70
3.05%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-17.70
-17.00
-4.12%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -4.12% vs -78.95% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-48.10
-44.40
-8.33%
Interest
1.90
2.90
-34.48%
Exceptional Items
0.00
-0.00
Consolidate Net Profit
-40.20
-44.60
9.87%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 9.87% vs -5.44% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Corbus Pharmaceuticals Holdings, Inc. stock-summary
stock-summary
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceuticals & Biotechnology
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Company Coordinates stock-summary
Company Details
500 RIVER RIDGE DRIVE , NORWOOD MA : 02062
stock-summary
Tel: 1 617 96301031 617 4157745
stock-summary
https://www.corbuspharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."